HCC, Hepatocellular Carcinoma
The Society welcomes NICEs endorsement of lebrikizumab as an additional treatment option for eligible individuals with moderate to severe atopic eczema, emphasizing the importance of providing diverse treatment choices to match patients needs. Jorgen Damsbo, General Manager at Almirall, UK, remarked, The NICE recommendation for lebrikizumab reflects its proven effectiveness with 4-weekly maintenance dosing and a favorable safety profile, aligning with our commitment to improving patients lives by helping them achieve better health. Professor Tony Bewley, Consultant Dermatologist at Barts Health NHS Trust and Honorary Professor of Dermatology at QMUL, emphasized the significant psychosocial burden of atopic dermatitis, noting that lebrikizumabs approval marks a crucial advancement that is welcomed by both patients and clinicians

Protein supplementation combined with resistance training leads to greater preservation of lean mass and strength than training alone. Key point: With adequate protein intake and resistance training, patients can maintainand sometimes increasestrength during GLP-1 therapy despite overall weight loss. Recovery and micronutrients Adequate sleep, hydration, and correction of deficiencies (including vitamin D when present) further support muscle function and recovery. Bottom Line: GLP-1 Medications Improve Body Composition Not Muscle Wasting Semaglutide and tirzepatide do not inherently cause muscle wasting. Most weight lost is fat , and body composition improves. Muscle wasting is primarily a risk of undernutrition , not GLP-1 therapy itself. Protein + resistance training is the most effective strategy to preserve muscle. At Potere Health MD, GLP-1 and GIP therapy is paired with evidence-based nutrition and strength guidance so weight loss is healthier, stronger, and more sustainable

hn ch tnh trng mua nhm hng gi, hng km cht lng bn nn tm n sanhangchinhhang.vn uy tn